RichardALarsonMD

Hematology • Chicago, IL

Professor of Medicine, University of Chicago Medicine

Join to view full profile

Dr. Larson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Larson's full profile

Already have an account?

Office
5841 S Maryland Ave
Chicago, IL 60637
Phone+1 888-824-0200

Fax+1 773-702-3002

Summary

Dr. Richard Larson is a hematologist-oncologist in Chicago, IL, and is affiliated with University of Chicago Medical Center. He received his medical degree from Stanford University School of Medicine and has been in practice >40 years. He specializes in hematologic oncology and is experienced in acute and chronic leukemia, chemotherapy, hematologic oncology, marrow transplantation and cellular therapy, and aplastic anemia.

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1980 - 1983
University of ChicagoResidency, Internal Medicine, 1977 - 1980
Stanford University School of MedicineClass of 1977

Certifications & Licensure

IL State Medical License 1978 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Super Doctor SuperDoctors.com

Clinical Trials

Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML Start of enrollment: 2009 Oct 01
Completed
Phase 2
Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation) Start of enrollment: 2009 Mar 01
Completed
Phase 1
A Study That Switched Patients From Imatinib to Nilotinib and Then Was Followed by Treatment Cessation Start of enrollment: 2013 Aug 12
Completed
Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Start of enrollment: 2018 Nov 22
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Developing Targeted Therapies for T Cell Acute Lymphoblastic Leukemia/Lymphoma.
Adam S DuVall, Austin Wesevich, Richard A Larson
Current Hematologic Malignancy Reports. 2023-12-01
930 citations
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.
Hartmut Döhner, Andrew H Wei, Frederick R Appelbaum, Charles Craddock, Courtney D DiNardo
Blood. 2022-09-22
314 citations
Prognostic Significance of the European LeukemiaNet Standardized System for Reporting Cytogenetic and Molecular Alterations in Adults With Acute Myeloid Leukemia
Krzysztof Mrózek, Guido Marcucci, Deedra Nicolet, Kati Maharry, Heiko Becker
Journal of Clinical Oncology. 2012-12-20

Abstracts/Posters

Outcomes of IDH-Mutated Advanced Phase Ph-Negative Myeloproliferative Neoplasms Treated with IDH Inhibitors
Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Ibrutinib and Venetoclax Target Distinct Subpopulation of CLL Cells: Rationale for Drug Combination and Implication of Minimal Residual Disease Eradication
Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Feasibility and Outcomes of T-Cell Depleted Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory AML and High Risk MDS
Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Long-Term Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Nilotinib Versus Imatinib: Enestnd 10-Year Analysis
Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Gene Expression Signature Predicts Deep Molecular Response (DMR) in Chronic Myeloid Leukemia (CML): An Exploratory Biomarker Analysis from ENESTnd
Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia
Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral TrialCl...
Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young ...
Richard A. Larson, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

ABL Tyrosine Kinase Inhibitors (TKIs) Are Associated with Increased Rho-Associated Kinase (ROCK) Activity That May Contribute to Vascular Toxicity in Patients with Chr...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Rando...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete R...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Comprehensive Molecular Profiling of FLT3-Mutated Acute Myeloid Leukemia (AML) Patients Treated within the Ratify Trial (Alliance C10603)
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
2012 Highlights of ASH in North America (Las Vegas, NV)
American Society of Hematology (ASH), Las Vegas, Nevada - 1/27/2012
2012 Highlights of ASH in North America (Austin, TX)
American Society of Hematology (ASH), Austin, Texas - 1/20/2012
Join now to see all

Authored Content

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 MutationJune 2017

Press Mentions

$1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia$
1st Patient Dosed with Cellectis’ Allogeneic UCART22 in Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaDecember 2nd, 2019
Uchicago Medicine Oncologist to Receive 2019 Henry M. Stratton Medal for Hematology ResearchAugust 13th, 2019